Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer

FLAURA2: EGFRm dynamics in NSCLC treated with osimertinibПодробнее

Developments in the management of EGFR-mutated NSCLCПодробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung CancerПодробнее

MARIPOSA: follow-up of lazertinib with amivantamab or osimertinib in EGFR-m NSCLCПодробнее

WCLC 2023 highlights: FLAURA2 and EGFR exon20-targeting TKIsПодробнее

TAGRISSO - 84% Reduction in Disease in Stage III EGFR-Mutated Lung Cancer: LAURA TrialПодробнее

Trials in EGFR Mutated NSCLC: Mariposa2 and Laura- 2024 Leading Developments in Lung CancerПодробнее

MARIPOSA Update - Amivantamab + Lazertinib in 1L EGFR mutated metastatic NSCLC.Подробнее

Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATICПодробнее

Metastatic EGFR+ NSCLC: Recent Developments - Targeted Therapies in Lung Cancer 2023Подробнее

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLCПодробнее

Second line treatment in activating EGFR non-small cell lung cancer, MARIPOSA - 2 | Onc BrothersПодробнее

First line treatment options for activating EGFR non-small cell lung Cancer | Dr. Alexander SpiraПодробнее

Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLCПодробнее

MARIPOSA-2: second interim OS of amivantamab and chemotherapy in EGFR-m NSCLCПодробнее

I was Diagnosed with Stage 4 Lung Cancer!Подробнее

MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinibПодробнее